The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Challenges of Guarantee-Time Bias
Open accessAbstract
The potential for guarantee-time bias (GTB), also known as immortal time bias, exists whenever an analysis that is timed from enrollment or random assignment, such as disease-free or overall survival, is compared across groups defined by a classifying event occurring sometime during follow-up. The types of events associated with GTB are varied and may include the occurrence of objective disease response, onset of toxicity, or seroconversion. However, comparative analyses using these types of events as predictors are different from analyses using baseline characteristics that are specified completely before the occurrence of any outcome event. Recognizing the potential for GTB is not always straightforward, and it can be challenging to know when GTB is influencing the results of an analysis. This article defines GTB, provides examples of GTB from several published articles, and discusses three analytic techniques that can be used to remove the bias: conditional landmark analysis, extended Cox model, and inverse probability weighting. The strengths and limitations of each technique are presented. As an example, we explore the effect of bisphosphonate use on disease-free survival (DFS) using data from the BIG (Breast International Group) 1-98 randomized clinical trial. An analysis using a naive approach showed substantial benefit for patients who received bisphosphonate therapy. In contrast, analyses using the three methods known to remove GTB showed no statistical evidence of a reduction in risk of a DFS event with bisphosphonate therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
A generalization of sampling without replacement from a finite universe
Horvitz, D. G., & Thompson, D. J. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483446 · Cited by 4,293 · cited 1×
“IPW An alternative analytic approach uses IPW in a two-stage model and is based on methods that were originally developed to address survey nonresponse.(21) These methods have been extended to a variety of settings, such as those when interventions are modified during follow-up according to an individual’s changing he…”
Methodvon Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Analysis of survival by tumor response.
Anderson, J. R., Cain, K. C., & Gelber, R. D. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.710 · Cited by 1,107
Self-citationAnalysis of survival by tumor response.
Anderson, J. R., & Davis, R. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.115 · Cited by 1,000
Landmark Analysis at the 25-Year Landmark Point
Dafni, U. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957951 · Cited by 569
Curtis, L. H., Hammill, B. G., Eisenstein, E. L., Kramer, J. M., & Anstrom, K. J. (2007) · Medical Care · doi:10.1097/mlr.0b013e31806518ac · Cited by 494
Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments
Hernán, M. A., Brumback, B., & Robins, J. M. (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753168154 · Cited by 493
Marginal Mean Models for Dynamic Regimes
Murphy, S. A., van der Laan, M. J., Robins, J. M., & Conduct Problems Prevention Research Group (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753382327 · Cited by 393
Simon, R., & Makuch, R. W. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030106 · Cited by 391
ipw: An R Package for Inverse Probability Weighting
Wal, W. M. V. D., & Geskus, R. B. (2011) · Journal of Statistical Software · doi:10.18637/jss.v043.i13 · Cited by 363
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
Swain, S. M., Jeong, J.-H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J., Vogel, V. G., Erban, J. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909638 · Cited by 338
(2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0783 · Cited by 244
Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator
Snapinn, S. M., Jiang, Q., & Iglewicz, B. (2005) · The American Statistician · doi:10.1198/000313005x70371 · Cited by 241
Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables
Anderson, J. R., Cain, K. C., & Gelber, R. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1000 · Cited by 228
Self-citationDo Oscar Winners Live Longer than Less Successful Peers? A Reanalysis of the Evidence
Sylvestre, M., Huszti, E., & Hanley, J. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-5-200609050-00009 · Cited by 140
Does Cardiac Transplantation Prolong Life? A Reassessment
Gail, M. H. (1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-5-815 · Cited by 137
Schneider, B. P., Zhao, F., Wang, M., Stearns, V., Martino, S., Jones, V. E., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8446 · Cited by 100
Souhami, L., Bae, K., Pilepich, M. V., & Sandler, H. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4052 · Cited by 89
Bouwhuis, M. G., Suciu, S., Testori, A., Kruit, W. H. J., Salès, F., Patel, P. M., Punt, C. J. A., Santinami, M., Spatz, A., ten Hagen, T. L. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6264 · Cited by 82
Amenorrhea from Breast Cancer Therapy — Not a Matter of Dose
Swain, S. M., Jeong, J., & Wolmark, N. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009616 · Cited by 72
Tricoci, P., Lokhnygina, Y. V., Berdan, L. G., Steinhubl, S. R., Gulba, D. C., White, H. D., Kleiman, N. S., Aylward, P. E., Langer, A., Califf, R. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.690081 · Cited by 53
Montomoli, J., Hamilton-Dutoit, S. J., Taylor, A., Erichsen, R., & Frøslev, T. (2012) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s34725 · Cited by 6
Research works printed but not linked: 3
- Shepherd LE, 2012, J Clin Oncol, 30, 7s
- 10.1200/JCO.2009.23.6000 · doi:10.1200/jco.2009.23.6000
- Van der Wal WM, 2011, J Stat Softw, 43, 1
Cited by
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02229 · Cited by 1,117
Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.04.014 · Cited by 1,097
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Metadata
- Authors
- Giobbie-Hurder, A., Gelber, R. D., & Regan, M. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-08-10
- Volume
- 31
- Issue
- 23
- Pages
- 2963-2969
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110847259
- Cited by
- 458
- References
- 24
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.